Acute respiratory failure in COVID-19 : is it "typical" ARDS?
In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) was identified in Wuhan, China. The World Health Organization (WHO) declared this outbreak a significant threat to international health. COVID-19 is highly infectious and can lead to fatal comorbidities especially acute respiratory distress syndrome (ARDS). Thus, fully understanding the characteristics of COVID-19-related ARDS is conducive to early identification and precise treatment. We aimed to describe the characteristics of COVID-19-related ARDS and to elucidate the differences from ARDS caused by other factors. COVID-19 mainly affected the respiratory system with minor damage to other organs. Injury to the alveolar epithelial cells was the main cause of COVID-19-related ARDS, and endothelial cells were less damaged with therefore less exudation. The clinical manifestations were relatively mild in some COVID-19 patients, which was inconsistent with the severity of laboratory and imaging findings. The onset time of COVID-19-related ARDS was 8-12 days, which was inconsistent with ARDS Berlin criteria, which defined a 1-week onset limit. Some of these patients might have a relatively normal lung compliance. The severity was redefined into three stages according to its specificity: mild, mild-moderate, and moderate-severe. HFNO can be safe in COVID-19-related ARDS patients, even in some moderate-severe patients. The more likely cause of death is severe respiratory failure. Thus, the timing of invasive mechanical ventilation is very important. The effects of corticosteroids in COVID-19-related ARDS patients were uncertain. We hope to help improve the prognosis of severe cases and reduce the mortality.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Critical care (London, England) - 24(2020), 1 vom: 06. Mai, Seite 198 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Xu [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acute respiratory distress syndrome |
---|
Anmerkungen: |
Date Completed 11.05.2020 Date Revised 13.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s13054-020-02911-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309592224 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309592224 | ||
003 | DE-627 | ||
005 | 20231225134239.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13054-020-02911-9 |2 doi | |
028 | 5 | 2 | |a pubmed24n1031.xml |
035 | |a (DE-627)NLM309592224 | ||
035 | |a (NLM)32375845 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Xu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Acute respiratory failure in COVID-19 |b is it "typical" ARDS? |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.05.2020 | ||
500 | |a Date Revised 13.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) was identified in Wuhan, China. The World Health Organization (WHO) declared this outbreak a significant threat to international health. COVID-19 is highly infectious and can lead to fatal comorbidities especially acute respiratory distress syndrome (ARDS). Thus, fully understanding the characteristics of COVID-19-related ARDS is conducive to early identification and precise treatment. We aimed to describe the characteristics of COVID-19-related ARDS and to elucidate the differences from ARDS caused by other factors. COVID-19 mainly affected the respiratory system with minor damage to other organs. Injury to the alveolar epithelial cells was the main cause of COVID-19-related ARDS, and endothelial cells were less damaged with therefore less exudation. The clinical manifestations were relatively mild in some COVID-19 patients, which was inconsistent with the severity of laboratory and imaging findings. The onset time of COVID-19-related ARDS was 8-12 days, which was inconsistent with ARDS Berlin criteria, which defined a 1-week onset limit. Some of these patients might have a relatively normal lung compliance. The severity was redefined into three stages according to its specificity: mild, mild-moderate, and moderate-severe. HFNO can be safe in COVID-19-related ARDS patients, even in some moderate-severe patients. The more likely cause of death is severe respiratory failure. Thus, the timing of invasive mechanical ventilation is very important. The effects of corticosteroids in COVID-19-related ARDS patients were uncertain. We hope to help improve the prognosis of severe cases and reduce the mortality | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 4 | |a Acute respiratory distress syndrome | |
650 | 4 | |a Berlin criteria | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Coronavirus | |
650 | 7 | |a L-Lactate Dehydrogenase |2 NLM | |
650 | 7 | |a EC 1.1.1.27 |2 NLM | |
650 | 7 | |a Creatine Kinase |2 NLM | |
650 | 7 | |a EC 2.7.3.2 |2 NLM | |
700 | 1 | |a Ma, Xiaochun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Critical care (London, England) |d 1997 |g 24(2020), 1 vom: 06. Mai, Seite 198 |w (DE-627)NLM097399787 |x 1466-609X |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2020 |g number:1 |g day:06 |g month:05 |g pages:198 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13054-020-02911-9 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2020 |e 1 |b 06 |c 05 |h 198 |